Phagenesis

Phagenesis is engaged in the development of a device to treat dysphagia, a condition that disables the safe swallowing of food.

Health and bio Commerce and retail

Latest funding

$42M Series B+ · March 4, 2024

Led by EQT Life Sciences · Source: startupintros.com

Latest round on record: Series B+, September 2024, amount undisclosed.

Total raised: $51.31M across 2 sourced rounds

All 3 rounds ↓

Website: phagenesis.com.

X: @Phagenyx · 1,211 followers.

LinkedIn: linkedin.com.

Categories: Health and bio Commerce and retail.

Sectors: Biotechnology, Health Care, Medical, Neuroscience.

Stage: Series B+.

Based in: Manchester, United Kingdom.

Founded: 2007.

Total raised: $51.31M in 2 sourced rounds.

Last round: Sep 1, 2024 · 802 days ago.

Headcount: 11–50 employees.

On Recent Funding since: Nov 8, 2026.

Signals

X account@Phagenyx · created Sep 8, 2010 (16 years old) · 1,211 followers

Website registeredJun 6, 2007 (19 years old)

TIMELINE · MONEY RAISED

Phagenesis | 391 days from X account to first raise on record

@Phagenyx·Raised $51M in 2 sourced rounds·1 signal before the first raise

Money raised, round by round (amounts linked to their source). Pins are dated signals; hover the icons for dates.

Funding rounds

September 1, 2024
Series B+ · amount undisclosed
Source: fundraisingfox.com
March 4, 2024
Series B+ · $42M
EEQT Life Sciences (lead), SSectoral Asset Management (lead), AAphelion Capital, BBritish Patient Capital, NNorthern Gritstone
Source: startupintros.com
October 4, 2011
Series B+ · $9.31M
IInventages Venture Capital Investment Inc. (lead)
Source: startupintros.com
September 8, 2010
X account created
June 6, 2007
Website created

Founders and team

CM
Conor Mulrooney Founder

LinkedIn
SH
Shaheen Hamdy Founder
CH
Chad Hoskins CEO
JH
Julie Humblet Head of Quality Assurance and Regulatory Affairs
SG
Scott Grant Vice President Therapy Development

Investors

Companies like Phagenesis

CCrafted
VVerve Motion$20M Series B+ · Dec 2023
TTRIMTECH Therapeutics$14M Seed · Jun 2026
NNuman$29M Series B+ · Jul 2025
DDiadem Biotherapeutics
CCureskin$20M Series B+ · Mar 2024

Other companies backed by EQT Life Sciences

NNouscom$135.04M Series B+ · Oct 2026
VVaderis Therapeutics$152M Series B+ · Aug 2026
RRQ Bio$115M Series A · Jun 2026
KKinaset Therapeutics$103M Series B+ · Jan 2026
FFoRx Therapeutics$50M Series A · Dec 2025
TTubulis$360M Series B+ · Oct 2025

EQT Life Sciences portfolio →

Sources and API

Every amount links to the page it came from. * Estimated from an accelerator's published standard deal, not a company-specific disclosure. How Recent Funding sources and verifies funding data. The same data as JSON: /api/v1/companies/phagenesis (get a free API key).